Companies › Akero Therapeutics
1 active drug program in 3 registered trials: 3 Phase 3; Gastroenterology; next expected readout Feb 2030.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Efruxifermin FGF21 receptor agonist | FGF21 | Phase 3 | NASH/MASH; NASH - Nonalcoholic Steatohepatitis; NASH With Fibrosis | Feb 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06161571 | Efruxifermin | Phase 3 | NASH/MASH | Gastroenterology | Mar 2026 |
| NCT06528314 | Efruxifermin | Phase 3 | NASH - Nonalcoholic Steatohepatitis | Gastroenterology | Feb 2030 |
| NCT06215716 | Efruxifermin | Phase 3 | NASH With Fibrosis | Gastroenterology | Feb 2033 |
GSK Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
Pharmicell Camurus VectivBio LyGenesis Mikrobiomik Healthcare Company
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.